NCT01094769

Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease

Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 48 (estimated)
• Sponsor: Baker Heart and Diabetes Institute · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether moxonidine is effective in reducing urine albumin levels in patients with diabetic kidney disease.

Detailed description

This study will investigate the effect of moxonidine in lowering urine albumin excretion and limiting further damage to the kidneys in patients with diabetic nephropathy. Reducing urine albumin excretion in type 2 diabetic patients is an indicator of successful treatment. Previous studies have shown that drugs that work in a similar fashion to moxonidine (intervene with the sympathetic nervous system)have been very effective in reducing the amount of albumin in the urine and are associated with long term renal and cardiovascular protection.

Conditions

• Diabetic Nephropathies

Interventions

Type	Name	Description
DRUG	Moxonidine	Patients will receive moxonidine treatment for 12 weeks, at a dose of 0.4mg/d for the first 6 weeks of treatment followed by up-titration of the dose to 0.6 mg/d for the final 6 weeks.
DRUG	Placebo	lactose capsule taken once daily

Timeline

• Start date: 2011-04-01
• Primary completion: 2020-01-01
• Completion: 2020-04-01
• First posted: 2010-03-29
• Last updated: 2023-09-14

Locations

1 site across 1 country: Australia